International Journal of Cancer

Cover image for Vol. 139 Issue 11

Editor-in-Chief: Professor Peter Lichter, DKFZ, Germany

Impact Factor: 5.531

ISI Journal Citation Reports © Ranking: 2015: 29/213 (Oncology)

Online ISSN: 1097-0215


Author Guidelines


QUICK LINKS

Author agreement form [upon acceptance]
Author services
Cell line confirmation form
Online submission
[req]
Open access order form
NIH Public Access policy
IJC EndNote style sheet



Author Guidelines


NEW UPDATE: September 2015

1. AIMS & SCOPE

2. MANUSCRIPT TYPES
2.1. Research Articles and Short Reports
2.2. Mini Reviews
2.3. Letters to the Editer
2.4. Special Section Papers

3. MANUSCRIPT PREPARATION
3.1 Manuscript text
3.2 References
3.3 Tables
3.4 Figures
3.5 Additional supporting information for online publication

4. MANUSCRIPT SUBMISSION
4.1 Original submissions
4.2 Submission of revised manuscripts

5. POLICIES
5.1 Authentication of cell lines
5.2 Authorship
5.3 Best-practice standards
5.4 Scientific integrity

6. EDITORIAL PROCESS
6.1 Submission
6.2 Review process
6.3 Appeal and rebuttals

7. INFORMATION ON ACCEPTANCE
7.1 Copyright
7.2 Author Agreement Form
7.3 Accepted articles
7.4 Proofs
7.5 Early View
7.6 OnlineOpen
7.7 Offprints
7.8 Note to NIH grantees

8. INFORMATION FOR PUBLICATION
8.1 Page charges
8.2 Colour charges

9. CONTACTS
9.1 Editorial Office
9.2 Publisher

10. REFERENCES

Author Guidelines

1. AIMS & SCOPE

The International Journal of Cancer (IJC) (http://www.intjcancer.org) is the official journal of the Union for International Cancer Control—UICC ; it appears twice a month. IJC invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original Research Articles and Short Reports under the following categories:

  • Cancer Epidemiology
  • Cancer Genetics and Epigenetics
  • Infectious Causes of Cancer
  • Molecular Cancer Biology
  • Tumor Immunology and Microenvironment
  • Tumor Markers and Signatures
  • Cancer Therapy and Prevention

IJC also publishes Mini Reviews, Letters to the Editor, and, several times per year, Special Sections consisting of invited articles on a timely topic in cancer research. IJC does not generally publish Case Reports. All types of articles undergo full peer review.

IJC is a member of the Committee on Publication Ethics (COPE) and endorses the recommendations issued by COPE and the International Committee of Medical Journal Editors (ICMJE).

2. MANUSCRIPT TYPES

2.1 Research Articles and Short Reports

Full research papers should be as concise as possible, without sacrificing documentation of results. Manuscripts containing pertinent and interesting observations concerning cancer research in general and reports on new observations or studies that do not warrant publication as a full research article will be considered as Short Reports. Research Articles and Short Reports should fit within the categories as outlined below and meet the standards stated therein: Cancer Epidemiology, Cancer Genetics and Epigenetics, Infectious Causes of Cancer, Molecular Cancer Biology, Tumor Immunology and Microenvironment, Tumor Markers and Signatures, and Cancer Therapy and Prevention.

2.1.1 Cancer Epidemiology
.Studies in human populations providing evidence that i) agents/exposures/host-factors pose a carcinogenic risk or are protective; ii) attempt to establish their causal role; iii) identify (sub-) populations at greatest risk; and iv) host–environment interactions are welcome. These include molecular cancer epidemiology approaches in which advanced laboratory methods are integrated. Randomized trials, case–control studies, cohort studies, studies of screening and diagnostic tests, and intervention studies will be considered. Each manuscript should clearly state an objective or hypothesis, the design, and methods (including the source of patients or participants with inclusion/exclusion criteria). Manuscripts reporting meta-analyses of previously published data might be considered, but are unlikely to be accepted unless they provide new insight into cancer etiology or prevention that was not previously available. Comprehensive omics studies in humans (e.g., profiling the genome, epigenome, transcriptome, proteome, metabolome, etc.) might be considered as well, but generally require functional verification of emerging candidate tumor-driving factors or, in case of novel markers and signatures, validation of those in independent patient cohorts (see “Tumor markers and signatures”).

If the authors are describing the results of observational studies, meta-analyses, and randomized trials, the corresponding standard reporting guidelines should be followed (see 5.3.5).

2.1.2 Cancer Genetics and Epigenetics
Genetic and epigenetic studies leading to the identification of factors and biochemical pathways relevant for the pathomechanism underlying tumor development are particularly welcome. Studies about new diagnostic tools are also within the scope if they hold promise of broad application.

2.1.3 Infectious Causes of Cancer
Contributions to this section should cover novel observations on the role of viral, bacterial, or parasitic infections in human cancers. Mechanistic aspects concerning direct or indirect modes of infectious carcinogens will be of particular interest. Gene expression control and functions of viral oncogenes as well as the discovery of new viruses or other infectious pathogens with growth-stimulating properties for infected cells or tissues will be considered. Indirect modes of carcinogenesis by infections are clearly of interest for the journal. Seroepidemiological and immunological studies related to infectious carcinogens will be considered if they present new data or demonstrate novel links between tumors and infections. The development of vaccines directed against tumor-linked infectious agents and their application is also of substantial interest. We also consider submissions on oncolysis by infectious agents.

2.1.4 Molecular Cancer Biology
Analytical and functional data on tumor cell characterization (in vitro and in vivo) and on tumor-stroma interactions are very welcome; in particular, novel molecular mechanisms of deregulated cancer cell metabolism and growth regulation, functional role of cancer stem cells for tumor development and progression, as well as novel mechanisms of tumor cell interactions with the microenvironment. Confirmatory findings on additional tumor types, stages, or sites without new functional, diagnostic, or therapeutic implications are not within the scope of the journal.

2.1.5 Tumor Immunology and Microenvironment
This section covers novel findings on the immunological relationship between tumor and host, including all aspects of cellular and humoral immunity directed at tumor and associated stromal cells of the tumor microenvironment. Experimental and clinical studies based on in vivo, ex vivo, and in vitro analysis will be considered. Particularly welcome are studies on new and improved preventive and therapeutic approaches exploiting innate and adaptive immune effects or mechanisms, such as vaccines, check point blockade, or adoptive cell therapy. The potential relevance of newly identified tumor cell-associated T cell epitopes (self- or neoantigen-derived) should be validated by functional in vivo studies.

2.1.6 Tumor Markers and Signatures
This section covers the area of prognostic, predictive, and diagnostic markers from molecular biology studies. We invite papers that explore the development and application of nucleic acid-based, protein-based, serological, and other approaches that identify biomarkers or signatures linked to cancer. Generally it is required that those markers and signatures are verified in independent patient cohorts and are compared to currently established markers used for the respective clinical application

2.1.7 Cancer Therapy and Prevention
Reports on new advances in cancer therapy in humans are welcome, especially the results of well-designed randomized trials involving novel (specifically including targeted) therapy strategies or those implicating molecular response indicators to classic or novel (targeted) therapeutics. If the authors are describing the results of a randomized controlled trial, we encourage use of the reporting guidelines in describing the study population (see Ann Intern Med 2010; 152: 726-32, doi:10.7326/0003-4819-152-11-201006010-00232) and we also welcome long-term follow-up studies. If the authors are describing the results of observational studies of therapy, the standards applicable in observational studies in epidemiology should be followed (see 5.3.5). IJC generally does not publish Case Reports.

For mechanistic studies on novel therapeutics we highly encourage having a strong in vivo aspect to support the translational potential of the study.

Novel mechanistic insights derived from experimental models and clinical observations on the cancer-preventive potential of chemical and biological agents, drugs, or food components that revealed a beneficial use in human intervention/cancer prevention studies also fit into this section.

2.2 Mini Reviews

Mini Reviews are primarily commissioned by the editors. Presubmission proposals will be considered, and the editors will then indicate whether the review is of potential interest for the journal.

2.3 Letters to the Editor

Comments on published papers, reports on controversial issues, also including negative data that are of general interest or that contradict commonly accepted concepts or hypotheses, will be considered for publication as Letters to the Editor. In the former case, the editors may invite the authors of the paper being questioned to respond, and both Letters may then be published.

2.4 Special Section Papers

Special Section Papers are commissioned by the editors. Authors will be given individual guidance in preparing their manuscripts.

3. MANUSCRIPT PREPARATION

IJC asks authors to ensure that their manuscripts meet the journal’s formal requirements as concerns presentation, formatting, and other accompanying documentation upon submission. In the event that papers do not fulfill these formal requirements, the editorial staff will “unsubmit” the manuscript. Authors will be asked to either upload files as needed or correct/revise the paper accordingly. Peer review will not commence until all requirements have been met.

3.1 Manuscript text

All manuscripts should be written in English (either British or American spelling). The text file should be in .doc or .rtf format and start with a title page (with short title, corresponding author contact information—address, fax, and email—, three to five key words, abbreviations used, and the appropriate article category). Research Articles and Short Reports should also include a brief description (max. 75 words) of the “Novelty and Impact” of the work on the title page of the paper. Upon acceptance, this will be presented in the journal table of contents and within the article as “What’s New”. All manuscripts except Letters should also contain an unstructured abstract (no headings/sections, maximum 250 words).

3.1.1 Research Articles and Short Reports
Research Articles and Short Reports should follow the IMRAD format (Introduction, Materials and Methods, Results, and Discussion). If appropriate, the results and discussion may be written as one section. Acknowledgments, References, Tables, and Figure Legends follow the body of the text.

Research Articles should not exceed 5,000 words in length (body of the text from Introduction to Discussion/Conclusions) and may contain a maximum of 50 references and 6 tables/figures in total. For Short Reports, these limitations are 2,500 words, 25 references, and 3 tables/figures in total. Please note that page charges are applied to Research Articles which exceed 8 typeset pages (see 8.1).

3.1.2 Mini Reviews
Mini Reviews should not exceed 4,000 words in length (from Introduction to Discussion/Conclusions) and should be limited to a maximum of 6 tables/figures in total. There is no limit on the number of references.

3.1.3 Letters to the Editor
Letters should include a title page (with the heading Letter to the Editor and corresponding author contact information—address, fax, and email) and begin with “Dear editor”. Replies to Letters should be entitled “Reply to: <title of the original letter>. Length should not exceed 1,000 words plus 1 figure or table and 10 references.

3.1.4 Special Section Papers
These papers are commissioned by the editors. Authors of Special Section Papers will be given individual guidance in preparing their manuscripts.

3.2 References

References are listed in a separate reference section immediately following the text. Follow Index Medicus2 for standard journal abbreviations (please see examples below). Number references sequentially in the order cited in the text; do not alphabetize. A reference cited only in a table or figure is numbered in the sequence established by the first mention in the text of the table or figure containing the reference. The corresponding author is responsible for verifying the references that are cited.

Reference to a personal communication or to work in preparation or submitted for publication is discouraged. However, if such a reference is essential and refers to a written communication, the source is cited parenthetically in the text (not in the reference section) with the comment "unpublished data" or "personal communication”. Written permission from the source that is cited must be sent to the Editorial Office. Reference to a paper accepted but not yet published is listed in the reference section as “in press”. “In press” references must be updated by the authors as soon as publication data are available.

For review, please provide names of ALL authors in the reference list. At proof stage, however, this will be reduced to 3 names to accommodate our print publication layout. Upon request, the editorial office can provide authors with an Endnote style sheet or it can be downloaded via the quick links above.

References to journal articles shall include: authors, article title and subtitle, journal abbreviation, year, volume number in Arabic numerals, and inclusive pages and appear in that order:

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386

Book references are listed as follows: authors, title, edition (if other than the first), volume (if more than one), city, publisher, year, pages:

2. Sobin LH, Gospodarowicz MK, Wittekind C, eds. TNM classification of malignant tumors, 7th ed. Chichester: Wiley, 2010. 310p

When referencing a book chapter, the order changes as follows: authors of the chapter, title of the chapter, "In:" editors/authors of the book, title of the book, edition (if there are more than one), volume (if there are more than one), city, publisher, year, and inclusive pages of the chapter:

3. Stilgenbauer S,Lichter P,Döhner H.Genetics of B-Cell Chronic Lymphocytic Leukemia. In: Faguet GB . Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. Heidelberg: Springer 2004:57–75

3.3 Tables

Tables can be included in the file “main document” or submitted as separate files. They are numbered using Arabic numerals. Submit tables preferably in doc or rtf format, exceptionally as xls, tif, or eps. All tables should be cited in the text. Each table requires a separate legend.

3.4 Figures

Authors should upload high-quality graphic data for figures. For use in the peer review process, figures may be submitted as tif, eps, ppt, gif, and jpg files. However, the preferred format is tif or eps, which would be required when the paper is accepted. Exceptionally at acceptance, ppt format is acceptable and pdf files may be provided for line art (see: http://exchanges.wiley.com/authors/digital-artwork_335.html).

Figures should be numbered using Arabic numerals. All figures, including supplementary figures, should be cited in the text. Each figure requires a separate legend.

All color figures will be reproduced in full color in the online edition of the journal at no cost to authors. Authors are requested to pay the cost of reproducing color figures in print (see 8.2).

The minimum requirements for resolution are: 1200 dpi/ppi for black and white images, such as line drawings or graphs, 300 dpi/ppi for picture-only photographs and at least 300 dpi for all color figures, and 600 dpi/ppi for photographs containing pictures and line elements, i.e., text labels, thin lines, and arrows. These resolutions refer to the output size of the file; if you anticipate that your images will be enlarged or reduced, resolutions should be adjusted accordingly.

3.5 Additional supporting information for online publication

Material that is not suitable for print publication such as very long tables, database information, movies, etc., can be published online as additional supporting information. The final decision to do so, however, lies with the editors. Please submit camera-ready files for this material as it will not be edited or altered in any way by the publisher.

4. MANUSCRIPT SUBMISSION

4.1 Original submissions

Please submit all new manuscripts online. Launch your web browser and go to http://mc.manuscriptcentral.com/ijc-wiley. Check for an existing account. If you are submitting for the first time, create a new account. Follow the step-by-step instructions for submission. Please note that all correspondence via ScholarOne Manuscripts automatically goes to the submitting author. Therefore, ideally, the corresponding author should submit the paper. Please upload the text in doc or rtf format, the tables in doc or rtf, and figures in tif or eps (exceptionally ppt or pdf for line art). It is permissible to upload everything in one file for review purposes but upon acceptance, individual files will be required.

During the online submission process, you will be asked to respond to questions concerning our journal policies. These submission questions and declarations have been designed to reflect best practices in scientific publication.

At the end of a successful submission, a confirmation screen with a manuscript number will appear and you will receive an e-mail confirming that the manuscript has been received by the journal. If this does not happen, please check your submission and/or contact technical support via the “Help” link.

4.1.1 Cover letter
Please introduce your work in a concise cover letter by addressing the following questions:

  • What is the aim of the study?
  • What are the significant and novel findings?

· How do these findings relate to the present state of the field?

This text can be used as a basis for the “Novelty and Impact” statements that are required both in the text file and on the online submission page.

The cover letter should also contain any other information about the manuscript or the authors that might be pertinent for the review process.

4.1.2 Authorship agreement and conflict of interest disclosure
Upon submission, the journal requires that the corresponding author ensures and takes responsibility that all coauthors agree to the submission to IJC and agree with the content and presentation of the paper. The corresponding author must also indicate at that time whether any author has a potential conflict of interest as per our policies. Space is provided for this on the ScholarOne Manuscripts submission page. Please note that upon acceptance, we require pen-on-paper signatures from all authors on our Author Agreement Form. We do not accept digital signatures.

4.1.3 Funding
We invite you to enter your sources of funding as part of the submission procedure using FundRef. By using this tool, standardized meta-data can be generated that helps streamline the processing of accepted articles that need to be deposited in funder databases such as PubMed Central. Furthermore, the funding data can be searched in other standardized databases.

4.1.4 Letters of permission
Permission is required from the appropriate investigators when “personal communication” or “unpublished data” is cited in the manuscript, or from another publisher if previously published material has been used in the manuscript.

4.2 Submission of revised manuscripts

4.2.1 Following decisions “minor revisions” and “major revisions”
If you have been invited to submit a revised manuscript, please submit it online via your author center. Instructions can be found there. Enter your point-by-point response to the reviewers’ comments at the “View and Respond” button. Upload only the copy of the revised paper in which all changes have been highlighted (underlined or marked).

4.2.2 Following decision “resubmit”
Please note that papers that have received a decision of “resubmit” usually require more extensive changes and should be resubmitted as a NEW manuscript. A point-by-point response should be included in the cover letter or uploaded as “supplementary material for review”. Please cite the number of the original paper in your cover letter.

5. POLICIES

5.1 Authentication of cell lines

As a consequence of the increasing use of cross-contaminated cell lines, the editors of IJC have taken measures to ensure that papers accepted for publication are not based on misidentified cells. Therefore, studies dealing with established human cell lines must provide a certificate of authentication (not older than 4 years) of the origin and identity of the cells. This is best achieved by DNA (STR or SNP) profiling (see below). For cell lines acquired within the last 4 years from a commercial source that guarantees cell line authenticity through in-house quality control measures, it is sufficient to provide their purchase order or invoice (N.B.: A published paper or a cell line data sheet available from the distributing company does not constitute sufficient documentation).

For authentication, authors should first check the list of confirmed misidentified and cross-contaminated cell lines to see whether the cell line they used is already known to be misidentified. Authors can either perform the profiling in their own laboratory (e.g., using a commercially available kit) or use the service provided by an approved laboratory or cell bank ( click here for an exemplary list of possible service providers ). The DNA profile then needs to be cross-checked with the DNA profile of the donor tissue (in case of a new cell line) or with the DNA profile of other continuous cell lines such as provided by the data bank available through www.dsmz.de/fp/cgi-bin/str.html (personal registration required). In case the authentication is performed in their own laboratory, we ask the authors to sign and upload the IJC form confirming that profiles for human cell lines used in the study have been compared with this list and cross-checked with the STR profile database. If an approved service provider or cell bank has performed the authentication, we ask that a written statement be included in their report confirming the identity of the cells.

The following cell lines are presently exempt from this rule:

  • Short-term cultures of human tumors
  • Murine/rat/rodent cell lines (as a catalog of DNA profiles is not yet available)
  • Tumor cell lines established in the course of the study that is being submitted. However, we strongly advise authors to establish a profile for these cell lines because, as outlined above, as soon as the line has been in use for more than 4 years, authentication will be required again.

5.2 Authorship

5.2.1 Authorship criteria
Authorship is defined according to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals 1. For submission, authors should meet these criteria and are welcome to report their individual contributions in the manuscript.

All authors must agree to any changes in authorship at any time during the review process, in particular if an author is being added or taken off the paper. For any changes in authorship after acceptance we require new author agreement forms from all authors.

We highly recommend that all authors provide their “Open Researcher and Contributor ID“(ORCID) when submitting a paper. Visit www.orcid.org for further information and to register.

5.2.2 Conflict of interest
A conflict of interest is defined as a situation in which a source of funding or any other financial and personal relationships might bias the authors’ work, in particular partial or complete funding from commercial sponsors (for example, commercial affiliations, patent-licensing arrangements). The editors reserve the right not to consider a manuscript if a sponsor has asserted control over the authors' right to publish their research results. See also the policy concerning Medical Writing Assistance.

5.2.3 Disclosures
I
In accordance with ICMJE recommendations1, if the authors have a potential financial or personal conflict of interest, they must (1) declare the conflict of interest as part of the submission process, (2) disclose it in the manuscript, either in the acknowledgments or in appropriate separate sections, and, (3) upon acceptance, submit and sign the Conflict of Interest form .

5.2.4 Medical writing assistance
According to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals1 and as outlined therein, “writing or other assistance should be acknowledged and contributions specified in the manuscript”. We do not accept Mini Reviews or editorials written by individuals paid for that service and who did not make a conceptual contribution to the work.

5.3 Best-practice standards

5.3.1 Animal studies
In order to adhere to accepted state-of–the-art good scientific reporting, e.g., ARRIVE criteria, research using animals should include the number and specific characteristics of these animals (including species, strain, sex, and genetic background) and the experimental, statistical, and analytical methods (including details of methods used to reduce bias such as randomization and blinding).

Approval of animal experiments should have been obtained by the appropriate local legal authorities.

5.3.2 Biological specimens
Collection, processing, and storage of biological specimens (cell lines, tissues, blood, serum/plasma, isolated cells, urine or other products derived from human beings) should adhere to good practice rules, as outlined for example by the Biospecimen Reporting for Improved Study Quality (BRISQ, http://www.ncbi.nlm.nih.gov/pubmed/21433001).

5.3.3 Gene, protein names and genetic profiling data
Please follow the official nomenclature rules for gene and protein names, such as gene names in italics, capital or lower case letters for human and murine genes, respectively, protein not in italics, etc. Authors should only use the official gene name as assigned by the respective gene nomenclature committee (for humans: HGNC at: www.genenames.org).

Regarding comprehensive data sets of genetic profiling (microarray) studies, raw data must be accessible in a publicly available database that requires MIAME format (for example, “GEO” or “Array Express”) upon submission of a paper. Authors are strongly encouraged to make available nucleic acid sequencing data that do not allow identification of individual patients on the basis of the sequence information, such as somatic mutation data obtained for gene panels, exomes, or the subfraction of protein-coding genes within whole genome sequence data. Such information can be provided via established databases (e.g., NCBI, EGA) or as supplementary information. At submission, therefore, please provide access to primary microarray or sequencing data, e.g., through the confidential password that is supplied by the database provider.

5.3.4 Human studies
Specific data on age, sex, and/or racial/ethnic groups should be provided, when appropriate, in describing outcomes of epidemiologic analyses or clinical trials; alternatively, it should be specifically stated that no sex-based or racial/ethnic-based differences were present.

A clear statement must be provided that the study was conducted after Human Experimentation Review and approved by an ethics committee, and that informed consent for using information and images was obtained.

Prospective clinical trials should be registered in a public trial registry and the registration number included in the paper.

5.3.5 Reporting guidelines
We encourage authors to use the standard reporting guidelines for their study, as applicable, and to consult and, if appropriate,upload the corresponding checklist (i.e., CONSORT-Randomized trials, STROBE- Observational studies, PRISMA-Meta-analyses, STARD – Diagnostic accuracy studies). IJC will publish the checklist as online supplementary material if a paper is accepted. We refer you to the Equator network for further information (http://www.equator-network.org/).

5.4 Scientific integrity

IJC has introduced procedures for checking the integrity of the data presented in the manuscript, as outlined below.

5.4.1 Duplicate submission and publication
In accordance with good scientific practice, a manuscript must not be submitted to more than one journal at the same time. In submitting to IJC you confirm that your manuscript has been submitted solely to this journal and is not published, in press, or submitted elsewhere. Likewise, as per ICMJE recommendations1, a paper that overlaps substantially with one already published without clear, visible reference to the previous publication would constitute duplicate publication.

5.4.2 Image manipulation
Fabrication or falsification of data, as outlined in the Clinical and Laboratory Images in Publication3 (CLIP principles, in particular no. 4) and endorsed by our publisher, Wiley (http://exchanges.wiley.com/ethicsguidelines), is strictly forbidden. Only minimal adjustments of original images are allowed, and any processing and modifications should be disclosed to the editors, who could require the original data or images at any time during or after the review process. Information present in the original images, however, should not be eliminated, and adjustments of brightness, contrast, or color can be accepted only if applied to the whole image. Grouping of images from different gel or different parts of a gel should be made explicit in the legend. IJC has introduced a procedure of checking accepted manuscripts to ensure the integrity of the data presented in the figures.

5.4.3 Plagiarism
Upon submission authors should confirm that the work they are presenting is their own and neither the text nor the data have been wrongfully appropriated. If alerted to any allegations of potential plagiarism or misappropriation of text, IJC may choose to apply the iThenticate software to the paper. However, we also make random checks for plagiarism in submitted manuscripts as part of our procedures for maintaining scientific integrity in IJC publications.

5.4.4 Potential scientific misconduct management
Scientific misconduct is a serious allegation and poses a great challenge to the scientific community. Inherent to the problem is also the danger of prejudging involved parties. In response to the increase in reports of scientific misconduct to editors and publishers, IJC has established a policy concerning the management of any such allegations reported to our journal so as to promote best practice in dealing with them objectively. However, for reasons of fairness and transparency and in reciprocal good faith concerning confidentiality and accountability, anyone who will report potential misconduct to us must state their name and affiliation, and disclose the basis for the allegation. Any further information that can be provided would be helpful in investigating such allegations. IJC will honor all requests to maintain confidentiality of personal information that is disclosed to us in such reports.

IJC endorses the ICMJE1 requirements and handles each case, including retractions, by following the COPE guidelines.

6 EDITORIAL PROCESS

6.1 Submission

All submissions are first checked by the Editorial Office staff to ensure they meet our formal requirements and are then assessed by the editors for scientific content. Papers not reaching a high enough level of priority or not fitting within the scope of the journal are not sent for review, and the authors are informed by e-mail, without detailed comments. In some cases, the authors may be offered the option to automatically transfer the paper, without reformatting, to the editor of the open access journal Cancer Medicine ( www.cancermedicinejournal.com).

6.2 Review process

Selected papers are sent for external review to experts in the field. The review process is single-blind, with the authors not being aware of the identity of the reviewers. Authors are invited to suggest potential reviewers for their paper (including address and email) as part of the online submission process. The authors also have the option of naming non-preferred reviewers. We aim to have a timely review process and usually reach a first decision in less than one month, although this can vary depending on the circumstances.

Under certain circumstances and upon special request, IJC is willing to conduct double-blind review of a manuscript. Please contact the Editorial Office about this when such a paper is submitted.

When a decision is reached, it is sent to the authors by email, including the comments of the referees. Possible decisions after review are: accept, minor revisions, major revisions, resubmit, and reject. In some cases, the authors of a paper rejected by IJC may be offered the option to automatically transfer the paper, along with any related peer reviews, to the editor of the open access journal Cancer Medicine ( www.cancermedicinejournal.com).

If upon review the editors are interested in considering the manuscript further after additional work is conducted, authors will be invited to resubmit it to IJC within 3 months. The revised manuscript should be accompanied by a detailed reply to reviewers’ comments, and changes performed should be highlighted in the text. Any questions concerning the requested changes/additional work or deadline extension should be addressed to the Editorial Office by fax or email before submission of the revised paper. Please always include the manuscript number in any correspondence and on any documents. Revised manuscripts may be assessed by the editors or returned to the original reviewers for re-evaluation. Therefore, the review process of the revised manuscript may take about a month in some cases. The editors maintain the option to reject a paper in a second or third round of revision if the specific concerns have not been addressed or if the paper still does not meet a high enough level of priority.

6.3 Appeals and rebuttals

Previously rejected papers will not be further considered, unless a prior appeal was made. Authors may appeal to an editors’ decision, shortly after notification, by writing an e-mail, and including a detailed reply to the reviewers’ comments. Each appeal will be evaluated by the editors, and a final decision will be communicated to the authors.

7 INFORMATION ON ACCEPTANCE

7.1 Copyright

Upon acceptance, authors identified as the formal corresponding author for the paper will receive an email prompting them to log in to Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

7.1.1 For authors signing the copyright transfer agreement
If the OnlineOpen option (see 7.6) is not selected, the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed below: https://mc.manuscriptcentral.com/societyimages/ijc-wiley/ECTA_A-IJC_SAMPLE.pdf

7.1.2 For authors choosing OnlineOpen
If the OnlineOpen option (see 7.6) is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution Non-Commercial License OAA

Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit:

http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html .

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.

For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:

Creative Commons Attribution License OAA

To preview the terms and conditions of these open access agreements please visit:

http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html .

7.1.3 For NIH employees only
Wiley will accept the NIH Publishing Agreement (for further information, see www.wiley.com/go/nihmandate ). For NIH grantees: please take note of the information in the check box on the eCTA regarding deposition in PubMed Central.

7.2 Author Agreement Form

Upon acceptance, we require pen-on-paper signatures from all authors on our Author Agreement Form. Each author who has checked the box on the Author Agreement Form indicating that he/she has a conflict of interest must also submit the Conflict of Interest form (p. 2 of the Author Agreement Form). These authors must provide a statement concerning any commercial sponsorship, commercial affiliations, stock/equity interests, or patent licenses of potential financial disclosure with the work presented in the submitted paper. The paper cannot be sent to the publisher until these forms are complete. Please also note that this disclosure must be indicated in the acknowledgments section or as a footnote in the final version of the paper.

7.3 Accepted articles

Further to acceptance in IJC and receiving final material, manuscripts are made publicly available online within 5 working days. At this stage accepted articles have been peer reviewed and accepted for formal publication, but have not been subject to copyediting, composition, or proof correction. The procedure provides for the earliest possible dissemination of research data following article acceptance. Accepted articles appear in pdf format only and are given a Digital Object Identifier (DOI), which means that they are in the public domain and can be cited and tracked. The DOI remains unique to a given article in perpetuity and can continue to be used to cite and access the article further to print publication. More information about DOIs can be found online at www.doi.org/faq.html

Neither the UICC nor Wiley can be held responsible for errors or consequences arising from the use of information contained in Accepted Articles; nor do the views and opinions expressed necessarily reflect those of the UICC or Wiley.

7.4 Proofs

Page proofs will be sent electronically to the Corresponding Author approx. 2 weeks after accepted article publication and should be returned to the Production Editor (jrnlprodIJC@cadmus.com) immediately. Significant textual alterations are unacceptable at proof stage without the written approval of the Editor-in-Chief, and they are likely to result in the delay of publication.

7.5 Early View

IJC is covered by the Publisher's Early View service, which allows for incremental online article publication in advance of print publication. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. Because they are in final form, no changes can be made subsequent to Early View publication. Early View articles can be cited and tracked by DOI.

7.6 OnlineOpen

OnlineOpen is available to authors of articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, click here

Authors wishing to make their articles OnlineOpen will be required to complete the online form.

Prior to acceptance, there is no requirement to inform the Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer review process and will be accepted or rejected based on their own merit.

7.7 Offprints

Corresponding authors will automatically receive a free PDF offprint by e-mail. Additional offprints can be ordered on the offprint order form, which accompanies the proofs.

7.8 Note to NIH grantees

Pursuant to NIH mandate, Wiley will post the accepted version of contributions authored by NIH grant-holders to PubMedCentral upon acceptance. This accepted version will be made publicy available 12 months after publication. For further information, click here

8 INFORMATION FOR PUBLICATION

8.1 Page charges

There is no fee for the first 8 pages of an article. A fee of US$150.00 for each page beyond the first 8 will be charged. (To calculate the number of printed pages your manuscript will become, count the number of text pages, allowing a page for each table and figure, and divide the total by 3.This gives a rough estimate.)

8.2 Color charges

Please be aware that the cost of color printing will be incurred by the author. The color fee is US$500 per page.

9 CONTACTS

9.1 Editorial Office

We invite inquiries to the Editorial Office at any time during the editorial process. For all matters concerning pre-submission, editorial policies and procedures, and general production matters, please contact the Heidelberg Editorial Office:

International Journal of Cancer
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 242, V962
69120 Heidelberg, Germany
Telephone: 49-6221-42-4800
Fax: 49-6221-42-4809
E-mail: intjcanc@dkfz.de
Web: www.intjcancer.org

9.2 Publisher

Specific questions regarding your proofs and copy editing of your manuscript can be handled by the publisher, Wiley. You can reach the publisher’s production department at jrnlprodIJC@cadmus.com

10 References

1 International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. Update December 2014, available at: http://www.icmje.org/icmje-recommendations.pdf
2 National Library of Medicine. List of journals indexed in index medicus. Washington, DC: US Government Printing Office [published annually].

3 Lang TA, Talerico C, Siontis GC. Documenting clinical and laboratory images in publications: the CLIP principles. Chest, 2012,141(6):1626-32.

SEARCH

SEARCH BY CITATION